Nicholas Investment Partners’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Nicholas Investment Partners’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-272,910	Closed	-$29.3M	–	215
2023 Q1	$29.3M	Sell	272,910 -10,336	-4%	-$1.19M	2.23%	6
2022 Q4	$31.2M	Sell	283,246 -205,989	-42%	-$13.4M	2.73%	1
2022 Q3	$28.9M	Sell	489,235 -42,058	-8%	-$1.92M	2.68%	1
2022 Q2	$15M	Buy	531,293 +344,213	+184%	+$9.98M	1.42%	18
2022 Q1	$7.06M	Buy	+187,080	New	+$7.39M	0.5%	72

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Nicholas Investment Partners's RXDX Position: Q2 2023 in Review

Nicholas Investment Partners sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 272,910 shares — an estimated $29.3M sold.

Nicholas Investment Partners first reported a position in RXDX in Q1 2022 and held it in 5 quarters. The position peaked at $31.2M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Nicholas Investment Partners reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Nicholas Investment Partners sold 272,910 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $29.3M.
Nicholas Investment Partners first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
Nicholas Investment Partners's Prometheus Biosciences, Inc. Common Stock position peaked at $31.2M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Nicholas Investment Partners's 13F filing for Q2 2023, filed 10 Aug 2023.